Background Loss-of-function variants in the gene encoding filaggrin (FLG) are major determinants of eczema. We hypothesized that weakening of the physical barrier in FLG-deficient individuals may potentiate the effect of environmental exposures. Therefore, we investigated whether there is an interaction between FLG loss-of-function mutations with environmental exposures (pets and dust mites) in relation to the development of eczema. Methods and Findings We used data obtained in early life in a high-risk birth cohort in Denmark and replicated the findings in an unselected birth cohort in the United Kingdom. Primary outcome was age of onset of eczema; environmental exposures included pet ownership and mite and pet allergen levels. In Copenhagen (n = 379), FLG mutation increased the risk of eczema during the first year of life (hazard ratio [HR] 2.26, 95% confidence interval [CI] 1.27–4.00, p = 0.005), with a further increase in risk related to cat exposure at birth amongst children with FLG mutation (HR 11.11, 95% CI 3.79–32.60, p < 0.0001); dog exposure was moderately protective (HR 0.49, 95% CI 0.24–1.01, p = 0.05), but not related to FLG genotype. In Manchester (n = 503) an independent and significant association of the development of eczema by age 12 mo with FLG genotype was confirmed (HR 1.95, 95% CI 1.13–3.36, p = 0.02). In addition, the risk increased because of the interaction of cat ownership at birth and FLG genotype (HR 3.82, 95% CI 1.35–10.81, p = 0.01), with no significant effect of the interaction with dog ownership (HR 0.59, 95% CI 0.16–2.20, p = 0.43). Mite-allergen had no effects in either cohort. The observed effects were independent of sensitisation. Conclusions We have demonstrated a significant interaction between FLG loss-of-function main mutations (501x and 2282del4) and cat ownership at birth on the development of early-life eczema in two independent birth cohorts. Our data suggest that cat but not dog ownership substantially increases the risk of eczema within the first year of life in children with FLG loss-of-function variants, but not amongst those without. FLG-deficient individuals may need to avoid cats but not dogs in early life.
References
[1]
Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, et al. (2006) Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 38: 441–446.
[2]
Marenholz I, Nickel R, Ruschendorf F, Schulz F, Esparza-Gordillo J, et al. (2006) Filaggrin loss-of-function mutations predispose to phenotypes involved in the atopic march. J Allergy Clin Immunol 118: 866–871.
[3]
Weidinger S, Illig T, Baurecht H, Irvine AD, Rodriguez E, et al. (2006) Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol 118: 214–219.
[4]
Weidinger S, Rodriguez E, Stahl C, Wagenpfeil S, Klopp N, et al. (2006) Filaggrin mutations strongly predispose to early-onset and extrinsic atopic dermatitis. J Invest Dermatol 127: 724–726.
[5]
Smith FJ, Irvine AD, Terron-Kwiatkowski A, Sandilands A, Campbell LE, et al. (2006) Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat Genet 38: 337–342.
[6]
Bisgaard H (2004) The Copenhagen Prospective Study on Asthma in Childhood (COPSAC): design, rationale, and baseline data from a longitudinal birth cohort study. Ann Allergy Asthma Immunol 93: 381–389.
[7]
Bisgaard H, Hermansen MN, Loland L, Halkjaer LB, Buchvald F (2006) Intermittent inhaled corticosteroids in infants with episodic wheezing. N Engl J Med 354: 1998–2005.
[8]
Bisgaard H, Hermansen MN, Buchvald F, Loland L, Halkjaer LB, et al. (2007) Childhood asthma after bacterial colonization of the airway in neonates. N Engl J Med 357: 1487–1495.
[9]
Halkjaer LB, Loland L, Buchvald FF, Agner T, Skov L, et al. (2006) Development of atopic dermatitis during the first 3 years of life: the Copenhagen prospective study on asthma in childhood cohort study in high-risk children. Arch Dermatol 142: 561–566.
[10]
Hanifin JM, Rajka G (1980) Diagnostic features of atopic dermatitis. Acta Derm Venereol 92: 44–47.
[11]
Paganelli R, Ansotegui IJ, Sastre J, Lange CE, Roovers MH, et al. (1998) Specific IgE antibodies in the diagnosis of atopic disease. Clinical evaluation of a new in vitro test system, UniCAP, in six European allergy clinics. Allergy 53: 763–768.
[12]
Kim JL, Elfman L, Mi Y, Johansson M, Smedje G, et al. (2005) Current asthma and respiratory symptoms among pupils in relation to dietary factors and allergens in the school environment. Indoor Air 15: 170–182.
[13]
Custovic A, Simpson BM, Murray CS, Lowe L, Woodcock A (2002) The National Asthma Campaign Manchester Asthma and Allergy Study. Pediatr Allergy Immunol 13(Suppl 15): 32–37.
[14]
Custovic A, Simpson A, Woodcock A (2004) Manchester cohort. Pediatr Pulmonol Suppl 26: 12–13.
[15]
Sandilands A, Terron-Kwiatkowski A, Hull PR, O'regan GM, Clayton TH, et al. (2007) Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema. Nat Genet 39: 650–654.
[16]
Williams HC, Burney PG, Strachan D, Hay RJ (1994) The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. II. Observer variation of clinical diagnosis and signs of atopic dermatitis. Br J Dermatol 131: 397–405.
[17]
Wahn U, Lau S, Bergmann R, Kulig M, Forster J, et al. (1997) Indoor allergen exposure is a risk factor for sensitization during the first three years of life. J Allergy Clin Immunol 99: 763–769.
[18]
Ownby DR, Johnson CC, Peterson EL (2002) Exposure to dogs and cats in the first year of life and risk of allergic sensitization at 6 to 7 years of age. JAMA 288: 963–972.
[19]
Lau S, Illi S, Sommerfeld C, Niggemann B, Bergmann R, et al. (2000) Early exposure to house-dust mite and cat allergens and development of childhood asthma: a cohort study. Multicentre Allergy Study Group. Lancet 356: 1392–1397.
[20]
Almqvist C, Egmar AC, Hage-Hamsten M, Berglind N, Pershagen G, et al. (2003) Heredity, pet ownership, and confounding control in a population-based birth cohort. J Allergy Clin Immunol 111: 800–806.
